ClinicalTrials.gg
RecruitingNCT06512428Updated Jul 22, 2024

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of simmitinib plus irinotecan liposome and irinotecan liposome in Advanced Esophageal Squamous Cell Carcinoma, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jul 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
103rd of 351
138 · median 70
Started
2024
with 49 others
Phase 2
212 of 401
96 open now
Primary completion
2026-01
later than 79 of 212 live
Registered
284th of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 103rd largest by planned enrollment of the 351 interventional ones that give a count, is one of 50 that started in 2024, is one of 212 in phase 2, reaches primary completion later than 79 of the 212 other live ones, and was the 284th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.

Read the detailed description

The experiment was divided into two stages. The first stage is dose escalation stage. Rapid titration and "3+3" dose escalation design were used to observe DLT of simmitinib plus irinotecan liposome, and MTD was determined. The second stage is a randomized controlled study. After RP2D was determined in the first stage, participants were randomly assigned to 3 groups in a 1:1:1 ratio, including simmitinib plus irinotecan liposome, irinotecan liposome, and irinotecan.

03

Conditions studied

  • Advanced Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood and voluntarily sign the ICF for this study;
  2. Age of 18-70 years (inclusive), male or female;
  3. Esophageal squamous cell carcinoma confirmed histologically or cytologically
  4. patients with disease progression after only first-line standard therapy(Standard treatment: chemotherapy with platinum plus fluorouracil or taxane combined with regimen .Progression during /neoadjuvant therapy or within 6 months of the last dose is considered a first-line standard treatment failure)
  5. At least one according to 1.1;
  6. (ECOG) performance status (PS) score of 0-1;
  7. Expected survival is more than 3 months
  8. Adequate organ function, defined as:

    (ANC) ≥ 1.5 × 10\^9/L; count (PLT) ≥ 75× 10\^9/L; (Hb) ≥ 90 g/L; (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × (ULN) (≤ 5.0 × ULN for patients with liver ); Serum total (TBIL) ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN and (CCr)≥60mL/min; (PT)、activated partial thromboplastin time (APTT)、international normalized ratio(INR)≤1.5 × ULN;

  9. Male and female patients of childbearing age must agree to take effective measures during treatment and within 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria

  1. Patients who have previously received any anti-tumor therapy within 4 weeks prior to the first dose;
  2. Patients who have previously received any within 4 weeks before the first use of the study treatment or are expected to received any live attenuated vaccine during the study;
  3. Prior systemic treatment with anti-VEGF drugs, irinotecan, or any other topoisomerase I inhibitor
  4. \<50%;
  5. ≤18.5 kg/m\^2
  6. Symptomatic central nervous system (CNS) or meningeal metastases;
  7. Patients with other types of malignant tumors within 5 years prior to the screening, except for radically resected, non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ, or other carcinoma in situ;
  8. Patients with bleeding tendency; active bleeding or a history of heavy bleeding within the past 6 months;
  9. Urine protein ≥ ++ and 24 h urine protein > 1.0g at screening period;
  10. Presence of any severe and/or uncontrolled disease before starting treatment;
  11. Severe lung disease within 6 months before first dosing ;
  12. Any active infection requiring antibiotics or hormones systemic treatment by intravenous infusion within 14 days prior to the first dose;
  13. Inability to swallow drugs orally, or presence of gastrointestinal disorders
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    simmitinib plus irinotecan liposome

    Drug: simmitinib plus irinotecan liposome

  • Experimental
    irinotecan liposome

    Drug: irinotecan liposome

  • Experimental
    irinotecan

    Drug: irinotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: DLT

    Dose Limited Toxicity

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28 (each cycle is 28 days)

  2. Dose Escalation Phase: AE

    Incidence rate of Adverse Event

    Time frame: From first dose to 30 days post the last dose

  3. Randomized controlled study phase: ORR

    Objective Response Rate (ORR) evaluated by investigators based on RECIST 1.1

    Time frame: 2 years

Secondary outcomes

  1. DCR

    Disease Control Rate

    Time frame: 2 years

  2. PFS

    Progression-free Survival

    Time frame: 2 years

  3. OS

    Overall Survival

    Time frame: 2 years

  4. DOR

    Duration of Objective Response

    Time frame: 2 years

  5. Area under plasma concentration (AUC)

    Area under the plasma concentration versus time curve (AUC) of simmitinib

    Time frame: 2 years

  6. Peak Plasma Concentration (Cmax)

    Peak Plasma Concentration (Cmax) of simmitinib

    Time frame: 2 years

  7. Time of peak plasma concentration (Tmax)

    Time of peak plasma concentration (Tmax) of simmitinib

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jan 2026, 22 months after the start.

Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 22, 2024
StartActual
Mar 15, 2024
Primary completionEst.
Jan 30, 2026
CompletionEst.
Jan 30, 2026
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06512428
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Mar 15, 2024
Primary completion
Jan 30, 2026 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Jul 22, 2024

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587
Yanqiao Zhang, Ph.D
principal investigator · The Second Affiliated Hospital of Harbin Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simmitinib · Irinotecan sucrosofate · Irinotecan

Start the discussion